A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

NCT ID: NCT07222137

Last Updated: 2025-12-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-31

Study Completion Date

2031-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 1

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Baricitinib

Participants will receive baricitinib orally

Group Type EXPERIMENTAL

Baricitinib

Intervention Type DRUG

Administered orally

Placebo

Participants will receive placebo orally

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Baricitinib

Administered orally

Intervention Type DRUG

Placebo

Administered orally

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LY3009104

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have a history of at least one documented occasion of at least two diabetes-related autoantibodies, AND one occasion of at least two diabetes-related autoantibodies obtained at screening or prescreening
* Have Stage 1b or Stage 2 type 1 diabetes
* Have a body weight of ≥8 kilograms (kg) (18 pounds) at screening

Exclusion Criteria

* Have any other type of diabetes
* Have uncontrolled high blood pressure
* Have had a heart attack, heart disease, stroke, or heart failure
* Have a history or high risk of venous thromboembolism, lymphoproliferative disease or malignancy
* Have a current or recent clinically serious infection
Minimum Eligible Age

1 Year

Maximum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eli Lilly and Company

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)

Role: STUDY_DIRECTOR

Eli Lilly and Company

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tallahassee Memorial HealthCare

Tallahassee, Florida, United States

Site Status

University of South Florida

Tampa, Florida, United States

Site Status

University of Iowa

Iowa City, Iowa, United States

Site Status

Iowa Diabetes and Endocrinology Research Center

West Des Moines, Iowa, United States

Site Status

Novak Center for Children's Health

Louisville, Kentucky, United States

Site Status

Children's Hospital of Philadelphia (CHOP)

Philadelphia, Pennsylvania, United States

Site Status

University of Virginia

Charlottesville, Virginia, United States

Site Status

Women's and Children's Hospital

Adelaide, , Australia

Site Status

Box Hill Hospital

Box Hill, , Australia

Site Status

Royal Brisbane and Women's Hospital

Brisbane, , Australia

Site Status

Centre for Children's Health Research

Brisbane, , Australia

Site Status

Royal Children's Hospital

Melbourne, , Australia

Site Status

The Royal Melbourne Hospital

Parkville, , Australia

Site Status

Perth Children's Hospital

Perth, , Australia

Site Status

Sydney Children's Hospital

Randwick, , Australia

Site Status

The Children's Hospital at Westmead

Westmead, , Australia

Site Status

UZ Brussel

Brussels, , Belgium

Site Status

Cliniques universitaires Saint-Luc

Brussels, , Belgium

Site Status

Antwerp University Hospital

Edegem, , Belgium

Site Status

UZ Leuven

Leuven, , Belgium

Site Status

CHU UCL Namur/Site Sainte Elisabeth

Namur, , Belgium

Site Status

Freire Pesquisa Clínica

Belo Horizonte, , Brazil

Site Status

Centro de Diabetes Curitiba

Curitiba, , Brazil

Site Status

Hospital Universitario Walter Cantidio

Fortaleza, , Brazil

Site Status

Cendi - Endocrinologia e Diabetes

Goiânia, , Brazil

Site Status

Centro de Pesquisa Clínica de Marília - CPCLIM

Marília, , Brazil

Site Status

Universidade Federal do Rio de Janeiro

Rio de Janeiro, , Brazil

Site Status

Instituto de Pesquisa Clinica

São Paulo, , Brazil

Site Status

CPCLIN

São Paulo, , Brazil

Site Status

IBTED - Tecnologia e Educação em Diabetes

São Paulo, , Brazil

Site Status

Hospital das Clinicas FMUSP

São Paulo, , Brazil

Site Status

Alberta Diabetes Institute

Edmonton, , Canada

Site Status

BC Diabetes Office

Vancouver, , Canada

Site Status

Oulun yliopistollinen sairaala

Oulu, , Finland

Site Status

Tampereen yliopistollinen sairaala

Tampere, , Finland

Site Status

Turku University Hospital

Turku, , Finland

Site Status

Hospices Civils de Lyon - Hopital Louis Pradel

Bron, , France

Site Status

Centre Hospitalier Sud Francilien

Corbeil-Essonnes, , France

Site Status

Hopital Claude Huriez - CHU de Lille

Lille, , France

Site Status

Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone

Marseille, , France

Site Status

Pitie Salpetriere University Hospital

Paris, , France

Site Status

Hopitaux Universitaires Paris Centre-Hopital Cochin

Paris, , France

Site Status

Hôpital Universitaire Necker Enfants Malades

Paris, , France

Site Status

Assistance Publique - Hopitaux de Paris (AP-HP) - Hopital Robert Debre - Centre Hospitalo Universitaire (C -T

Paris, , France

Site Status

CHU Rangueil

Toulouse, , France

Site Status

Universitaetsklinikum Augsburg

Augsburg, , Germany

Site Status

Universitaetsklinikum Carl Gustav Carus, Technischen Universitaet Dresden

Dresden, , Germany

Site Status

Hannoversche Kinderheilanstalt

Hanover, , Germany

Site Status

TUM Klinikum

München, , Germany

Site Status

Yitzhak Shamir Medical Center

Beer Yaacov, , Israel

Site Status

Soroka Medical Center

Beersheba, , Israel

Site Status

Rambam Health Care Campus

Haifa, , Israel

Site Status

Institute of Diabetes, Technology and Research - Clalit Health

Herzliya, , Israel

Site Status

Hadassah Medical Center

Jerusalem, , Israel

Site Status

Meir Medical Center

Kfar Saba, , Israel

Site Status

Schneider Children's Medical Center

Petah Tikva, , Israel

Site Status

Rabin Medical Center

Petah Tikva, , Israel

Site Status

Sheba Medical Center

Ramat Gan, , Israel

Site Status

Kaplan Medical Center

Rehovot, , Israel

Site Status

Sourasky Medical Center

Tel Aviv, , Israel

Site Status

Ospedale Pediatrico Salesi

Ancona, , Italy

Site Status

IRCCS - AOU di Bologna

Bologna, , Italy

Site Status

Ospedale Microcitemico

Cagliari, , Italy

Site Status

Azienda Ospedaliera Universitaria Meyer IRCCS

Florence, , Italy

Site Status

Ospedale San Raffaele

Milan, , Italy

Site Status

University of Naples Federico II

Napoli, , Italy

Site Status

University of Naples Federico II

Napoli, , Italy

Site Status

Azienda Ospedaliero Universitaria Maggiore della Carità

Novara, , Italy

Site Status

Azienda Ospedale - Università Padova

Padua, , Italy

Site Status

Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento

Verona, , Italy

Site Status

Abeno Medical Clinic

Abeno, , Japan

Site Status

Saitama Medical University Hospital

Iruma, , Japan

Site Status

Nippon Medical School Musashi Kosugi Hospital

Kawasaki, , Japan

Site Status

Yamanashi Prefectural Central Hospital

Kofu, , Japan

Site Status

Seino Internal Medicine Clinic

Kōriyama, , Japan

Site Status

Jinnouchi Hospital

Kumamoto, , Japan

Site Status

Nagano Municipal Hospital

Nagano, , Japan

Site Status

Soleil Chikusa Clinic

Nagoya, , Japan

Site Status

Nakakinen clinic

Naka, , Japan

Site Status

Niigata University Medical & Dental Hospital

Niigata, , Japan

Site Status

Diabeter - Rotterdam

Rotterdam, , Netherlands

Site Status

Haukeland Universitetssjukehus

Bergen, , Norway

Site Status

Akershus Universitetssykehus

Lørenskog, , Norway

Site Status

Oslo Universitetssykehus Ullevål

Oslo, , Norway

Site Status

Oslo Universitetssykehus Aker

Oslo, , Norway

Site Status

Stavanger Universitetssykehus

Stavanger, , Norway

Site Status

Medical Network Spółka z o.o. WIP Warsaw IBD Point Profesor Kierkuś

Warsaw, , Poland

Site Status

2Ca Braga

Braga, , Portugal

Site Status

Unidade Local de Saude de Matosinhos

Matosinhos Municipality, , Portugal

Site Status

Centro Materno Infantil do Norte

Porto, , Portugal

Site Status

ULSAM - Hospital de Santa Luzia

Viana do Castelo, , Portugal

Site Status

Unidade Local De Saude De Gaia/Espinho E.P.E.

Vila Nova de Gaia, , Portugal

Site Status

OSI Ezkerraldea-Enkarterri-Cruces - Hospital Universitario Cruces

Barakaldo, , Spain

Site Status

Hospital Sant Joan de Déu

Esplugues de Llobregat, , Spain

Site Status

Hospital Universitario Ramón y Cajal

Madrid, , Spain

Site Status

Skånes Universitetssjukhus Malmö

Malmo, , Sweden

Site Status

Universitetssjukhuset Örebro

Örebro, , Sweden

Site Status

Queen Elizabeth Hospital Birmingham

Birmingham, , United Kingdom

Site Status

Birmingham Children's Hospital

Birmingham, , United Kingdom

Site Status

Addenbrooke's Hospital

Cambridge, , United Kingdom

Site Status

Noah's Ark Children's Hospital for Wales

Cardiff, , United Kingdom

Site Status

University Hospital of Wales

Cardiff, , United Kingdom

Site Status

Queen Elizabeth University Hospital

Glasgow, , United Kingdom

Site Status

Royal London Hospital

London, , United Kingdom

Site Status

St. George's Hospital

London, , United Kingdom

Site Status

The John Radcliffe Hospital

Oxford, , United Kingdom

Site Status

Southampton General Hospital

Southampton, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Belgium Brazil Canada Finland France Germany Israel Italy Japan Netherlands Norway Poland Portugal Spain Sweden United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

Role: CONTACT

Phone: 1-317-615-4559

Email: [email protected]

Physicians interested in becoming principal investigators please contact

Role: CONTACT

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Related Links

Access external resources that provide additional context or updates about the study.

https://trials.lilly.com/en-US/trial/662883

A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults (BARICADE-DELAY)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025-521797-34-00

Identifier Type: CTIS

Identifier Source: secondary_id

I4V-MC-JAJJ

Identifier Type: OTHER

Identifier Source: secondary_id

27404

Identifier Type: -

Identifier Source: org_study_id